Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.
Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.